Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 28, 2025

Primary Completion Date

July 30, 2027

Study Completion Date

July 30, 2027

Conditions
Hepatitis C
Interventions
DRUG

Glecaprevir/pibrentasvir

100 mg glecaprevir and 40 mg pibrentasvir for a total daily dose of glecaprevir 300 mg/pibrentasvir 120 mg

Trial Locations (10)

10457

Bronx-Lebanon Hospital Center, The Bronx

10461

Jacobi Medical Center, The Bronx

11794

SUNY Stony Brook, Stony Brook

21287

Johns Hopkins University Baltimore, Baltimore

32209

Univ. of Florida Jacksonville, Jacksonville

60614

Lurie Children's Hospital of Chicago, Chicago

77030

Baylor College of Medicine//Texas Children's Hospital, Houston

80045

University of Colorado Denver, Aurora

90089

USC LA, Los Angeles

90095

David Geffen School of Medicine at UCLA, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

AbbVie

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH